<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002269</url>
  </required_header>
  <id_info>
    <org_study_id>073A</org_study_id>
    <secondary_id>AMP-700</secondary_id>
    <nct_id>NCT00002269</nct_id>
  </id_info>
  <brief_title>A Multicenter, Double-Blind, Controlled Study to Evaluate Ampligen</brief_title>
  <official_title>A Multicenter, Double-Blind, Controlled Study to Evaluate Ampligen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HEM Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate ampligen at two dosage levels given twice weekly in combination with zidovudine
      (AZT) versus AZT alone in individuals with HIV-related immune dysfunction defined as T4 count
      between 100 and 300 cells/mm3.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ampligen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients must have:

          -  HIV-1 seropositivity.

          -  Absolute number of T4 cells 100-300 cells/mm3.

          -  Given informed consent.

          -  Zidovudine (AZT) therapy for 6 months prior to study entry.

          -  At least one of the listed HIV-related clinical symptoms or opportunistic infections:

          -  weight loss &gt; 10 percent, unexplained diarrhea, unexplained intermittent fever, oral
             candidiasis &gt; 1 month, decreased Karnofsky, oral hairy leukoplakia, chronic fatigue.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following conditions or symptoms are excluded:

          -  Evidence of AIDS.

          -  Intercurrent acute medical disorder.

        Concurrent Medication:

        Excluded:

          -  Chemotherapy for Kaposi's sarcoma (KS).

          -  Aspirin.

          -  Non-steroidal anti-inflammatory drugs.

        Patients with the following are excluded:

          -  Inability to return for treatment and evaluation for 12 months.

          -  Intercurrent acute medical disorder.

          -  Evidence of AIDS.

          -  Receiving chemotherapy for Kaposi's sarcoma (KS).

          -  Unwilling or unable to give informed consent.

        Required:

          -  Zidovudine (AZT).

        Required at least 6 months prior to study entry:

          -  Zidovudine (AZT).

        Active drug abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Miami Veterans Administration Med Ctr</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences Univ</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MCP Hahnemann Univ Hosp</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nelson Tebedo Community Clinic</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Patricia Salvato</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 1991</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>ampligen</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>poly(I).poly(c12,U)</mesh_term>
    <mesh_term>Poly I-C</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

